The use of androgens in menopause.
Recent increase in the potential role for androgen supplementation in the menopause, as well as the availability of nontraditional, over-the-counter food supplements containing DHEA, currently touted for postmenopausal health, have raised the need for clinicians to have a working knowledge of both potential benefits and risks of androgen replacement as a supplement to traditional hormone replacement therapy. There is compelling evidence that androgen levels are reduced after bilateral oophorectomy. The degree of androgen reduction after natural menopause may be less, and the onset of this decrease more gradual in this population. A decrease in androgen levels has been proposed as one etiology for decreased libido, and there is some evidence to support androgen use in oophorectomized women suffering from diminished libido. Such evidence is mixed, however, in naturally menopausal women. Androgen replacement may provide additional relief of menopausal symptoms in some patients, but this evidence is also inconsistent. Initial studies seem to support a perceived enhancement in psychological well-being, but confirmatory, long-term studies are still needed. Available evidence suggests a positive impact on bone density with the use of some androgen preparations, but no consistent benefit from DHEA has been demonstrated. Although androgen therapy can induce decreases in HDL cholesterol levels, the clinical impact of this is not yet known. Currently, there is little support for the routine use of androgen supplementation in the menopause. Additionally, a number of adverse events may be associated with androgen use. Careful patient selection, with comprehensive evaluation to sort out other possible medical or psychological conditions, should be undertaken before the initiation of androgen replacement. Currently available preparations are limited in number and flexibility in dosing, but there is ongoing effort to develop new delivery systems and therapeutics so that options available in the future may allow for enhanced availability and efficacy.
Hoeger
K M
KM
University of Rochester, Department of Obstetrics & Gynecology, NY 14642-8668, USA.
Guzick
D S
DS
D000328:Adult; D000339:Affect / Q000187:drug effects; D000728:Androgens / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D007989:Libido / Q000187:drug effects; D008593:Menopause / Q000502:physiology; D008875:Middle Aged; D014666:Vasomotor System / Q000187:drug effects
D000728:Androgens